Challenges and opportunities in the Chinese herbal drug industry

Natural Products: Drug Discovery and Therapeutic Medicine

Volumn , Issue , 2005, Pages 229-250

  Jia, Wei ^a   Zhang, Lixin ^b,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^c SynerZ Pharmaceuticals Inc   (United States)

Author keywords

Complementary and alternative medicine (CAM); globalization; integration; modernization; preventive therapy; traditional Chinese medicine (TCM)

Indexed keywords

EID: 84862809309     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59259-976-9_10     Document Type: Chapter

References (130)

1. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003;100(13):7977-7982.
2. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1, 117-123.
3. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science 2000;287, 1969-1973.
4. Lenz GR, Nash HM, Jindal S. Chemical ligands, genomics and drug discovery. Drug Discovery Today 2000;5, 145-156.
5. Kalgutkar AS, Crews BC, Rowlinson SW., et al. Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors. Proc Natl Acad Sci USA 2000;97:925-930.
6. Nanda A, St. Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 2004;16:44-49.
7. Review of Global Pharmaceutical Industry in 2002. Institute of the South Economic Research of SFDA, 2003.
8. Service RF. Surviving the blockbuster syndrome. Science 2004;303(5665):1796-1799.
9. Lathers CM. Challenges and opportunities in animal drug development: a regulatory perspective. Nat Rev Drug Discov 2003;2(11):915-918.
10. Szuromi P, Vinson V, Marshall E. Rethinking drug discovery. Science 2004:1795.
11. Knight V, Sanglier JJ, Di Tullio D, et al. Diversifying microbial natural products for drug discovery. Appl Microbiol Biotech 2003;62:446-458.
12. Landers P. Cost of developing a new drug increases to about $1.7 billion. The Wall Street Journal 12/8/2003.
13. Kennedy D. Drug discovery. Science 2004;303(5665):1729.
14. Kitano H. Systems biology: a brief overview. Science. 2002;295, 1662-1664.
15. Kanehisa M, Goto S, Kawashima S, Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Res 2002;30:42-46.
16. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-365.
17. Brent R. Genomic biology. Cell 2000;100:169-183.
18. Kitano H. Computational systems biology. Nature 2002;420(6912):206-210.
19. Jorgensen WL. The many roles of computation in drug discovery. Science 2004;303(5665):1813-1818.
20. Shaheen RM, Tseng WW, Davis DW, et al. Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 2001;61:1464-1468.
21. Zhang P. Cell cycle control and development: redundant roles of cell cycle regulators. Curr Opin Cell Biol 1999;11:655-662.
22. Chan-Hui PY. From PGx to molecular diagnostics and personalized medicine. Drug Discov Today 2003;8(18):829-831.
23. Van Haselen RA, Reiber U, Nickel I, Jakob A, Fisher PA. Providing complementary and alternative medicine in primary care: the primary care workers' perspective. Complement Ther Med 2004;12(1):6-16.
24. Giordano J, Boatwright D, Stapleton S, Huff L. Blending the boundaries: steps toward an integration of complementary and alternative medicine into mainstream practice. J Altern Complement Med 2002;8(6):897-906.
25. McClure MW. An overview of holistic medicine and complementary and alternative medicine for the prevention and treatment of BPH, prostatitis, and prostate cancer. World J Urol 2002;20(5):273-284.
26. Hong CD. Complementary and alternative medicine in Korea: current status and future prospects. J Altern Complement Med 2001;7:S33-S40.
27. Dossey BM. Holisitic nursing: taking your practice to the next level. Nurs Clin North Am 2001;36(1):1-22.
28. Larson L. Natural selection. Trustee 2001;54(4):6-12.
29. Norred CL, Zamudio S, Palmer SK. Use of complementary and alternative medicines by surgical patients. AANA J 2000;68(1):13-18.
30. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997. J Am Med Assoc 1998;280:1569-1575.
31. Kessler RC, Davis RB, Foster DF, et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 2001;135:262-268.
32. Goldbeck-Wood S, Dorozynski A, Lie LG, et al. Complementary medicine is booming worldwide. Br Med J 1996;313:131-133.
33. Carlsson M, Arman M, Backman M, Flatters U, Hatschek T, Hamrin E. Evaluation of quality of life/life satisfaction in women with breast cancer in complementary and conventional care. Acta Oncol 2004;43(1):27-34.
34. Engel LW, Straus SE. Development of therapeutics: opportunities within complementary and alternative medicine. Nat Rev Drug Discov 2002;1(3):229-237.
35. Weiger WA, Smith M, Boon H, Richardson MA, Kaptchuk TJ, Eisenberg DM. Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 2002;137(11):889-903.
36. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prods 1997;60:52-60.
37. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66(7):1022-1037.
38. Mendelson R, Balick MJ. The value of undiscovered pharmaceuticals in tropical forests. Econ Bot 1995;49:223-228.
39. Dictionary of Natural Products. Chapman and Hall/CRC, London: 2001.
40. Henkel T, Brunne RM, Müller H, Reichel F. Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew Chem Int Ed Engl 1999;38:643-647.
41. Berdy J. Are actinomycetes exhausted as a source of secondary metabolites? Proc. 9th Internat Symp Biol Actinomycetes, Part 1. Allerton, New York: 1995; pp. 3-23.
42. Roessner CA, Scott AI. Genetically engineered synthesis of natural products: from alkaloids to corrins. Ann Rev Microbiol 1996;50:467-490.
43. Fenical W, Jensen PR. Marine microorganisms: a new biomedical resource. In: Attaway DH, Zaborsky OR (eds), Marine Biotechnology I: Pharmaceutical and Bioactive Natural Products. Plenum, New York: 1993; pp. 419-475.
44. Kiefer DM. A century of pain relief. Todays Chem Work 1997;6(12):38-42.
45. Clark AM. Natural products as a resource for new drugs. Pharm Res 1996;13:1133-1141.
46. Tyler VE, Brady LR, Robbers JE. Pharmacognosy, 9th edn. Lea & Febiger, Philadelphia: 1988.
47. Schultz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physician's Guide to Herbal Medicine, 4th edn. Springer, Berlin: 2001.
48. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985;228:1049-1055.
49. Horwitz SB. Personal recollections on the early development of taxol. J Nat Prod 2004;67(2):136-138.
50. Clark J. Regulation of natural health products challenged. CMAJ. 2004;170(8):1217.
51. Blumenthal M. In: Blumenthal M et al (eds), The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines 17. Austin, Texas: American Botanical Council, 1998.
52. Unschuld PU. The past 1000 years of Chinese medicine. Lancet 1999;354 Suppl: SIV9.
53. Opara EI. The efficacy and safety of Chinese herbal medicines. Br J Nutr 2004;91(2):171-173.
54. Kam PC, Liew S. Traditional Chinese herbal medicine and anaesthesia. Anaesthesia 2002;57(11):1083-1089.
55. Ernst E. Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review. J Intern Med 2002;252(2):107-113.
56. Normile D. Asian medicine. The new face of traditional Chinese medicine. Science 2003;299(5604):188-190.
57. Lampert N, Xu Y. Chinese herbal nephropathy. Lancet 2002;359(9308):796- 797.
58. Hesketh T, Zhu WX. Health in China. Traditional Chinese medicine: one country, two systems. BMJ 1997;315(7100):115-117.
59. Wang ZG, Ren J. Current status and future direction of Chinese herbal medicine. Trends Pharmacol Sci 2002;23(8):347-348.
60. Bodeker G. Lessons on integration from the developing world's experience. BMJ 2001;322(7279):164-167.
61. Scheid V. The globalization of Chinese medicine. Lancet 1999;354 Suppl: SIV10.
62. Research Report of Chinese Pharmaceutical Market Analysis of Chinese Herbal Drug Industry, WAN Fang Database Co. Ltd., 2003.
63. Summary of Chinese Herbal Pharmaceutical Technology and Process. Information Center of State Drug Administration, 2002.
64. Liu ZH, Li ZJ. The Industrial Developing Strategy of Chinese Herbal Drug Modernization. Traditional Chinese Medicine, Beijing: 2003.
65. Chinese Medicines and Health Products Report. Ming Jing Market Research & Consultation Co., Ltd., 2002.
66. Developing and Future Trend of National and International Pharmaceutical Industry in 2002. Institute of Economic Research of NDRC, 2003.
67. Huang LQ, Cui GH, Chen ML, et al. Study on complex system of Chinese material medica GAP fulfilling-the situation, problems, and prospects of Chinese material medica germplasm. China J Chin Mate Med 2002;27:481-483.
68. Huang LQ, Cui GH, Dai RW. Study on complex system of Chinese Materia Medica GAP fulfilling. China J Chin Mater Med 2002;27:1-3.
69. Yuan CQ, Wang NH, Lu Y. Conservation of endangered medicinal plants in China. In: Zhang ED, Zheng HC (eds), Conservation of Endangered Medicinal Wildlife Resources in China. Second Military Medical University Press, Shanghai: 2000; pp. 25-32.
70. Wang LX, Xiao LL. Significance of medicinal botany to the conservation of endangered species. In: Zhang ED, Zheng HC (eds), Conservation of Endangered Medicinal Wildlife Resources in China. Second Military Medical University Press, Shanghai: 2000; pp. 83-86.
71. Liu HG, Zhan YH, Chen JC. The cultivation and GAP of Chinese Materia Medica in Hubei province in China. J Hubei College TCM 2001;3:45-46.
72. Shang MF, Zhu Y. The situation of cultivation base of Chinese materia medica in China. Res Inform Trad Chin Med 2000;2(10):23-27.
73. Wang WQ, Liu CS, Sun ZR, et al. The study of GAP and its application in Chinese materia medica. Res Inform Trad Chin Med 2001;3(10):14-16.
74. Wang JM, Liu HM, Jiang CZ, et al. The establishment of GAP cultivation base. Chin Pharm 2002;16:32-34.
75. Yao ZG, Fu YQ. Recent questions and improved measures of Chinese Prepared Medicinal Herbs. Lishizhen Mater Med Res 2002;13(9):552-553.
76. Economic Operating Analytic Report of Pharmaceutical Industry in 2001. Bureau of Economic Operation of SETC, 2002.
77. Review and Prospect of the Pharmaceutical Companies on the Stock Market. Bureau of Economic Operation of SETC, 2003.
78. Shao YD, Gao WY, Jia W, et al. The quality control of plan extract. China J Chin Mater Med 2003;28(10):899-903.
79. Jia W, Gao W Y, Xiao PG. The discussion of internationalization of Chinese herbal drugs. China J Chin Mater Med 2002;27(9):645-648.
80. Fan QL. Science of Prescription. Shanghai TCM University Press, Shanghai: 2002.
81. Sasaki H. International Senior Forum of Traditional Chinese Medicines & Botanical Products. Speech Collection: 38-41, Hangzhou, China, 2001.
82. Lord GM, Cook T, Arlt VM, et al. Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001;358:1515-1516.
83. Ma HM, Zhang BL, Xu ZP, et al. Experimental research on the renal toxicity of Guan-mu-tong (Aristolochiae manshuriensis). Clin Pharmacol Tradit Chin Med 2001;12:404-409.
84. Pub L no. 75-717, 52 Stat 1040 (1938)
85. USC 9 (Food, Drug and Cosmetic Act 1938).
86. Pub L no. 87-781, § 102 (c), 76 Stat 780 (1962)
87. (codified at 21 USC § 355 (d) (5)) (Kefauver Harris Amendment of 1962).
88. Pub L no. 103-417, 108 Stat 4325 (1994)
89. USC 231 (The Dietary Supplement Health and Education Act of 1994).
90. Bass IS, Raubicheck CJ. Marketing Dietary Supplements. Washington DC: Food and Drug Law Institute, 2000.
91. Federal Register. House Government Reform Committee. Six Years After the Enactment of DSHEA: The Status of National and International Dietary Supplement Regulation (March 20, 2001).
92. Qi G. Protective effect of gypenosides on DNAand RNA of rat. Acta Pharmacol Sin 2000;21:1193-1196.
93. Yun TK. Panax ginseng-a non-organ-specific cancer preventive? Lancet Oncol 2001;2:49-55.
94. Shibata S. Chemistry and cancer preventing activities of ginseng saponins and some related triterpenoid compounds. J Korean Med Sci 2001;16:S28-S37.
95. Yun TK. Update from Asia. Asian studies on cancer chemoprevention. Ann NY Acad Sci 1999;889:157-192.
96. Zhao X, et al. Effects of ginsenoside of stem and leaf in combination with choline on improving learning and memory of Alzheimer disease. Chin Pharmacol Bull 2000;16:544-547.
97. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applicagtions. Altern Ther Health Med 2001;7:70-90.
98. Gao Y, et al. Effect of allicin on the regulation of VEGF mRNA expression in human hepatocellular carcinomal cells. Chin Pharmacol Bull 2001;17:531-536.
99. Xu JP, Rui YC, Li TJ. Antagonistic effects of ginkgo biloba extract on adhesion of monocytes and neutrophils to cultured cerebral microvascular endothelial cells. Zhongguo Yaoli Xue Bao 1999;20:423-425.
100. Deng R. General research situation of long-circulation nanoparticles. Chin Pharm J 2001;36:511-513.
101. Nie QH, Luo XD, Zhang JZ, Su Q. Current status of severe acute respiratory syndrome in China. World J Gastroenterol 2003;9(8):1635-1645.
102. Fugh-Berman A. Herbs and dietary supplements in the prevention and treatment of cardiovascular disease. Prev Cardiol 2000;3(1):24-32.
103. Koo LC. Concepts of disease causation, treatment and prevention among Hong Kong Chinese: diversity and eclecticism. Soc Sci Med 1987;25(4):405-417.
104. Bibeau G. From China to Africa: the same impossible synthesis between traditional and western medicines. Soc Sci Med 1985;21(8):937-943.
105. Wang WK, Wang YY. Biomedical engineering basis of traditional Chinese medicine. Med Prog Technol 1992;18(3):191-197.
106. Ernst E. Complementary medicine: evidence base, competence to practise and regulation. Clin Med 2003;3(5):481-482.
107. Ernst E. Herbal medicines put into context. BMJ 2003;327(7420):881-882.
108. Hohmann N, Koffler K. Risk of adverse reactions from contaminants in Chinese herbal medicines can be minimized by using quality products and qualified practitioners. Int J Environ Health Res 2002;12(1):99-100.
109. Chan TY, Critchley JA. Usage and adverse effects of Chinese herbal medicines. Hum Exp Toxicol 1996;15(1):5-12.
110. Chan TY. Monitoring the safety of herbal medicines. Drug Saf 1997;17(4):209-215.
111. Matsumoto K, Mikoshiba H, Saida T. Nonpigmenting solitary fixed drug eruption caused by a Chinese traditional herbal medicine, ma huang (Ephedra Hebra), mainly containing pseudoephedrine and ephedrine. J Am Acad Dermatol 2003;48(4):628-630.
112. Li XM, Sampson HA. Novel approaches for the treatment of food allergy. Curr Opin Allergy Clin Immunol 2002;2(3):273-278.
113. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355(9198):134-138.
114. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage 2000;20(5):374-387.
115. Ernst E. Toxic heavy metals and undeclared drugs in Asian herbal medicines. Trends Pharmacol Sci 2002;23:136-139.
116. Xu QF, Fang XL, Chen DF. Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 2003;84(2-3):187-192.
117. Zhang BL, Wang YY, Chen RX. Clinical randomized double-blinded study on treatment of vascular dementia by jiannao yizhi granule. Zhongguo Zhong Xi Yi Jie He Za Zhi 2002;22(8):577-580.
118. Chen LC, Chen YF, Chou MH, Lin MF, Yang LL, Yen KY. Pharmacokinetic interactions between carbamazepine and the traditional Chinese medicine Paeoniae Radix. Biol Pharm Bull 2002;25(4):532-535.
119. Fugh-Berman A, Kronenberg F. Complementary and alternative medicine (CAM) in reproductive-age women: a review of randomized controlled trials. Reprod Toxicol 2003;17(2):137-152.
120. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137(10):805-813.
121. Tang JL, Zhan SY, Ernst E. Review of randomised controlled trials of traditional Chinese medicine. BMJ 1999;319(7203):160-161.
122. Koop CE. The future of medicine. Science 2002;295(5553):233.
123. Rahman K. Historical perspective on garlic and cardiovascular disease. J Nutr 2001;131(3 s):977S-979S.
124. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95(7):526-532.
125. Pappas SG, Jordan VC. Raloxifene for the treatment and prevention of breast cancer? Expert Rev Anticancer Ther 2001;1(3):334-340.
126. Honig SF. Tamoxifen for the reduction in the incidence of breast cancer in women at high risk for breast cancer. Ann NY Acad Sci 2001;949:345-348.
127. Goldstein SR. The effect of SERMs on the endometrium. Ann NY Acad Sci 2001;949:237-242.
128. Prout MN. Breast cancer risk reduction: what do we know and where should we go? Medscape Womens Health 2000;5(5):E4.
129. Osborne MP. Chemoprevention of breast cancer. Surg Clin North Am 1999;79(5):1207-1221.
130. Goldstein SR. Selective estrogen receptor modulators: a new category of compounds to extend postmenopausal women's health. Int J Fertil Womens Med 1999;44(5):221-226.